/MRUS
MRUS Stock - Merus N.V.
Healthcare|BiotechnologyNASDAQ
$97.01+0.22%
+$0.21 (+0.22%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-0.0%upside
Target: $97.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRUS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$96.04 – $97.98
TARGET (TP)$97.00
STOP LOSS$89.25
RISK/REWARD1:-0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.06
52W High$97.14
52W Low$33.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $34.88M | $39.81M | $38.84M | $43.15M | $24.51M |
| Gross Profit | $12.96M | $29.31M | $28.88M | $-43,121,688 | $-32,823,404 |
| Gross Margin | 37.2% | 73.6% | 74.4% | -99.9% | -133.9% |
| Operating Income | $-262,626,275 | $-141,800,272 | $-149,459,488 | $-79,052,913 | $-62,113,730 |
| Net Income | $-207,854,187 | $-140,343,746 | $-122,522,076 | $-58,704,537 | $-70,000,941 |
| Net Margin | -595.9% | -352.6% | -315.5% | -136.1% | -285.6% |
| EPS | $-3.35 | $-3.00 | $-2.92 | $-1.73 | $-2.92 |
Company Overview
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$74
Average Target
↓ 23.8% Downside
Now
$38
Low
$74
Average
$112
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 17th 2025 | Barclays | Initiation | Overweight | $112 |
| August 25th 2025 | Alliance Global Partners | Initiation | Buy | $90 |
| February 13th 2025 | Piper Sandler | Initiation | Overweight | $84 |
| February 7th 2025 | Wells Fargo | Initiation | Overweight | $91 |
| November 21st 2024 | Goldman | Initiation | Buy | $73 |
| October 24th 2024 | UBS | Initiation | Buy | $72 |
| March 28th 2024 | Truist | Initiation | Buy | $69 |
| March 4th 2024 | Needham | Reiterated | Buy | $65← $42 |
| November 2nd 2023 | Canaccord Genuity | Initiation | Buy | $45 |
| August 21st 2023 | TD Cowen | Initiation | Outperform | - |
| August 2nd 2022 | Stifel | Initiation | Buy | $38 |
Earnings History & Surprises
MRUSBeat Rate
56%
Last 18 quarters
Avg Surprise
+3.6%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-1.23
Q4 2025
EPS Surprise History
Q1 24
-40.5%
$-1.04vs$-0.74
Q2 24
+27.2%
$-0.59vs$-0.81
Q3 24
-6.6%
$-0.81vs$-0.76
Q4 24
-5.6%
$-0.95vs$-0.90
Q1 25
+53.9%
$-0.41vs$-0.89
Q2 25
-20.7%
$-1.40vs$-1.16
Q3 25
-90.6%
$-2.23vs$-1.17
Q4 25
0.0%
$-1.23vs$-1.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.24 | — | — | — |
Q4 2025 | Oct 31, 2025 | $-1.23 | $-1.23 | 0.0% | = MET |
Q3 2025 | Aug 5, 2025 | $-1.17 | $-2.23 | -90.6% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-1.16 | $-1.40 | -20.7% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.89 | $-0.41 | +53.9% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.90 | $-0.95 | -5.6% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.76 | $-0.81 | -6.6% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.81 | $-0.59 | +27.2% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.74 | $-1.04 | -40.5% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.73 | $-0.43 | +41.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.88 | $-0.66 | +25.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.02 | $-0.86 | +15.7% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.83 | $-1.81 | -118.1% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.63 | $-0.53 | +15.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.62 | $-0.13 | +79.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.62 | $-0.43 | +30.6% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.58 | $-0.34 | +41.4% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.62 | $-0.39 | +37.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.59 | $-0.71 | -20.3% | ✗ MISS |
Latest News
Merus And Halozyme Form Non Exclusive Global Collaboration Supporting Potential Commercialization Of Subcutaneous Petosemtamab
📈 PositiveBenzinga•Nov 17, 2025, 12:05 PM•Also:
Genmab To Offer $1.5B Of Senior Secured Notes Due 2032 And $1B Of Senior Unsecured Notes Due 2033, The Company Also Launched The Syndication Of A New $2B Senior Secured Term Loan In Addition To A $1B Senior Secured Term Loan Facility And $500M Senior Secured Revolving Credit Facility To Finance The Merus Acquisition
➖ NeutralBenzinga•Nov 10, 2025, 12:25 PM•Also:
Merus Announces Interim Clinical Data From Ongoing Phase 2 Trial Of Bispecific Antibody Petosemtamab In Metastatic Colorectal Cancer In Combination With FOLFOX/FOLFIRI
➖ NeutralBenzinga•Oct 24, 2025, 02:04 PM
Merus Reports Interim Phase 2 Results for Petosemtamab in Metastatic Colorectal Cancer
➖ NeutralBenzinga•Oct 14, 2025, 11:34 AM
Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
📈 PositiveBenzinga•Oct 13, 2025, 04:04 PM
Leerink Partners Downgrades Merus to Market Perform, Raises Price Target to $97
📉 NegativeBenzinga•Oct 6, 2025, 11:26 AM
Guggenheim Downgrades Merus to Neutral, Lowers Price Target to $97
📉 NegativeBenzinga•Sep 30, 2025, 02:19 PM
Canaccord Genuity Downgrades Merus to Hold, Raises Price Target to $97
➖ NeutralBenzinga•Sep 30, 2025, 01:38 PM•Also:
Wells Fargo Downgrades Merus to Equal-Weight, Raises Price Target to $97
➖ NeutralBenzinga•Sep 30, 2025, 01:14 PM
UBS Downgrades Merus to Neutral, Raises Price Target to $97
➖ NeutralBenzinga•Sep 30, 2025, 11:52 AM
LifeSci Capital Downgrades Merus to Market Perform, Announces $97 Price Target
➖ NeutralBenzinga•Sep 30, 2025, 11:46 AM
Barclays Downgrades Merus to Equal-Weight, Lowers Price Target to $97
📉 NegativeBenzinga•Sep 30, 2025, 11:43 AM•Also:
HC Wainwright & Co. Downgrades Merus to Neutral, Lowers Price Target to $97
📉 NegativeBenzinga•Sep 30, 2025, 09:20 AM
GMAB stock has given up its prior loss. Genmab shares were trading lower after the company announced it will acquire Merus for $8 billion.
➖ NeutralBenzinga•Sep 29, 2025, 07:30 PM•Also:
Truist Securities Downgrades Merus to Hold, Raises Price Target to $97
➖ NeutralBenzinga•Sep 29, 2025, 06:25 PM
Needham Downgrades Merus to Hold, Maintains Price Target to $96
➖ NeutralBenzinga•Sep 29, 2025, 02:07 PM
Citigroup Downgrades Merus to Neutral, Lowers Price Target to $97
➖ NeutralBenzinga•Sep 29, 2025, 12:28 PM•Also:
Genmab shares are trading lower after the company announced it will acquire Merus for $8 billion.
📉 NegativeBenzinga•Sep 29, 2025, 11:25 AM•Also:
Merus shares are trading higher after Genmab agreed to acquire the company for $97 per share.
📈 PositiveBenzinga•Sep 29, 2025, 11:25 AM•Also:
Genmab To Acquire Merus For $8B In All-Cash Deal Adding Breakthrough Therapy Petosemtamab To Late-Stage Pipeline
📈 PositiveBenzinga•Sep 29, 2025, 05:53 AM•Also:
Frequently Asked Questions about MRUS
What is MRUS's current stock price?
Merus N.V. (MRUS) is currently trading at $97.01 per share. The stock has moved +0.22% today.
What is the analyst price target for MRUS?
The average analyst price target for MRUS is $97.00, based on 1 analyst.
What sector is Merus N.V. in?
Merus N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MRUS's market cap?
Merus N.V. has a market capitalization of $7.36 billion, making it a mid-cap company.
Does MRUS pay dividends?
No, Merus N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CORT
Corcept Therapeutics Incorporated
$83.76
Mkt Cap: $8.8B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to MRUS for comparison